Oncology Other denied as not medically necessary by Blue Cross Blue Shield?

For Anthem Blue Cross Blue Shield Marketplace (Individual & Commercial) members, oncology drugs administered under the medical benefit are delegated to Carelon Medical Benefits Management (formerly AIM Specialty Health) for prior authorization review. Carelon uses an evidence- and value-based approach utilizing cancer treatment pathways, provider-preferred clinical review, and enhanced reimbursement and pathway adherence reporting, covering approximately 85% of spending on cancer drugs across therapeutic and supportive drugs. Carelon Cancer Treatment Pathways are cancer treatment regimens intended to support quality cancer care and reduce unneeded variation in care and cost, developed through a rigorous process of integrating evidence-based literature with physician practice guidelines. Pathways identify a subset of regimens supported by clinical evidence and practice guidelines, selected based on clinical benefit (efficacy), safety/side effects (especially those leading to hospitalizations and impacting quality of life), strength of national guideline recommendations, and cost of regimens. Off-pathway requests are reviewed individually: the platform approves requests that align with policy and pathways, and board-certified medical oncologists and nurses consult on off-pathway requests and alert providers to enhanced reimbursement opportunities. For some health plans, requested services are reviewed in accordance with client medical policies and clinical guidelines; if a request is received that is not a Carelon Pathway regimen, it may be reviewed and authorized if determined to be medically necessary, with reference to NCCN Clinical Practice Guidelines in Oncology. Critical elements include confirming the diagnosis based on a complete evaluation including history, physical examination, relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention, with anticipated benefit outweighing potential harms. Self-administered/oral oncology drugs under the pharmacy benefit are reviewed against CarelonRx clinical criteria approved by the CarelonRx Pharmacy and Therapeutics Committee, an independent external committee of practicing physicians, pharmacists, and clinicians from leading academic medical centers with expertise in evidence-based medicine across all major clinical specialties.

- Carelon's own framework permits off-pathway approval when medically necessary: the treating oncologist determines if a Pathway regimen is the best option or whether, given the patient's unique circumstances, another regimen is a better choice, and non-Pathway requests may be authorized if determined to be medically necessary, referencing NCCN Clinical Practice Guidelines in Oncology. - Cite the specific NCCN Clinical Practice Guideline (Category 1 or 2A recommendation) supporting the requested regimen for the patient's histology, stage, and biomarker status — Carelon explicitly references NCCN as an authoritative source for medical necessity determinations. - Submit biomarker/pathology reports (e.g., NGS, IHC, FISH) confirming the targetable alteration required by the FDA label or NCCN guideline; Carelon requires confirmation of the diagnosis based on complete evaluation including review of relevant laboratory studies and diagnostic testing. - For step-therapy denials, document contraindication, intolerance, or prior failure of preferred agents; step therapy requires that the member has tried an alternative therapy first, or that the prescriber has clinically documented why the member cannot take the alternative therapy. - Demonstrate that benefit outweighs harm and delay would worsen outcomes: the anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to treatment. - Invoke clinician authority and individualization: medical necessity decisions may change as new information is provided or based on unique aspects of the patient's condition, and the treating clinician has final authority and responsibility for treatment decisions and for justifying medical necessity. - For Marketplace ACA plans, cite the ACA's essential health benefit protections and the plan's obligation to follow recognized compendia (NCCN Drugs & Biologics Compendium, AHFS, Micromedex DrugDex) for off-label oncology indications, which Carelon's pathway framework already incorporates via NCCN alignment.

## Why BCBS May Deny an Oncology Drug for "Medical Necessity" and How to Appeal

Blue Cross Blue Shield medical-necessity denials for oncology medications typically occur when a plan's utilization review determines that the submitted clinical documentation does not satisfy the specific coverage criteria in its oncology medical policy. This can happen even when your oncologist is certain the treatment is appropriate — the denial often reflects a documentation gap rather than a genuine clinical disagreement. Common gaps include incomplete staging information, missing biomarker results, inadequate documentation of prior treatment lines, or a prescriber letter that does not map directly to the plan's published criteria.

### Why This Denial Is Appealable

Medical-necessity denials are highly fact-specific and frequently reversed on appeal when the right documentation is submitted. Under ERISA §503 full-and-fair review, you are entitled to present all clinical evidence on appeal — including information that was not part of the original authorization request. An oncologist-authored letter that directly addresses each criterion in BCBS's oncology policy, supported by chart documentation, is the cornerstone of a successful appeal.

### Federal Appeal Framework

• Internal appeal: File within the timeframe stated on your denial notice. ERISA §503 entitles you to a full-and-fair review, including the right to review all documents the plan relied on and to submit new evidence.
• External review (ACA §2719): If the internal appeal is denied, request independent external review within the four-month window from your final internal denial.
• Expedited review: If delay would jeopardize your health or ability to continue a treatment cycle, request expedited review. Expedited external review typically resolves within 72 hours.

### Documentation to Gather

1. BCBS oncology medical policy: Request the specific medical policy for the drug or drug class at issue. Map every listed criterion to your chart evidence before writing the appeal. 2. Diagnosis and staging records: Pathology reports, imaging, and biomarker or genomic profiling results that precisely establish your diagnosis and stage. 3. Prior-treatment line history: A chronological summary of all prior oncology treatments with dates, regimens, best response, and reason for discontinuation — demonstrating that you have met any prior-therapy requirements. 4. Prescriber medical-necessity letter: A detailed letter from your oncologist that addresses each BCBS coverage criterion one by one, citing specific chart findings. 5. Guideline concordance: A statement from your oncologist that the proposed treatment aligns with the applicable guideline organization's recommendations for your cancer type and stage.

### Criteria-Mapping Approach

| BCBS Coverage Criterion | Chart Evidence | |---|---| | Confirmed diagnosis and histology | [Pathology report date and findings] | | Stage / extent of disease | [Staging workup results] | | Biomarker / genomic eligibility (if required) | [Test result and date] | | Prior treatment line(s) completed | [Each regimen, dates, outcome] | | Treatment aligns with recognized guidelines | [Oncologist letter, guideline org reference] |

A criteria-mapped appeal — where every policy requirement is answered with a specific chart fact — turns the appeal into a checklist the reviewer can verify, rather than a narrative they must interpret.